PDS Biotechnology Corp — Director's Dealing 2016

Feb 19, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Edge Therapeutics, Inc. (EDGE)
CIK: 0001472091
Period of Report: 2016-02-16

Reporting Person: Faleck Herbert J (Chief Medical Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-02-16	Stock Option (Right to Purchase)	$6.99	A	110000	Acquired	2026-02-16	Common Stock (110000)	Direct

Footnotes

F1: This option, representing a right to purchase a total of 110,000 shares of Common Stock, will become exercisable on February 16, 2017, with 25% vesting on that date and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to continued service to the Issuer through each vesting date.